Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25173357 | 1.00 | KMT2A (0.56) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL5917388 | 0.92 | KMT2A (0.51) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL6731866 | 0.86 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL6443477 | 0.85 | KMT2A (0.49) | KMT2AEPHX2CASP3 | |
| SCHEMBL29368747 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL1764428 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL31010836 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL31714178 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL2654395 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL31536519 | 0.84 | KMT2A (0.58) | KMT2AEPHX2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281149-B2 | Modulators of G-protein coupled receptors | CARMOT THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | CARMOT THERAPEUTICS INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024110757-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | WO | disclosed |
| CN-117980325-A | Modulators of G-protein coupled receptors | 卡莫特治疗学股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4337682-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022241287-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220195017-A1 | PATHOGEN BINDING METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-06-23 | — | — | US | disclosed |
| US-11021709-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2013071049-A1 | GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY | TRUSTEES OF BOSTON COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130064895-A1 | Amphiphilic Peptides and Peptide Particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013028843-A1 | PEPTIDE NANOPARTICLES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012177986-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2012-12-27 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-0800516-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORP (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-5866592-A | Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same | NIPPON STEEL CORPORATION (JP) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | GIPR, GLP1R, GCGR | KMT2A 2726/4885EPHX2 3706/4885MDM4 4625/4885 |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | KMT2A 4350/4885EPHX2 1788/4885MDM4 4361/4885 |
| US-12281149-B2 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | KMT2A 2726/4885EPHX2 3721/4885MDM4 4636/4885 |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | KMT2A 2726/4885EPHX2 3721/4885MDM4 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.